Document is current
Any future updates will be listed below
-
Authors
Willis, Sophie E. https://orcid.org/0000-0002-4341-4655
Winkler, Claudia https://orcid.org/0000-0002-4970-7299
Roudier, Martine P.
Baird, Tarrion
Marco-Casanova, Paola
Jones, Emma V.
Rowe, Philip
Rodriguez-Canales, Jaime
Angell, Helen K.
Ng, Felicia S. L.
Waring, Paul M.
Hodgson, Darren
Ledermann, Jonathan A.
Weberpals, Johanne I.
Dean, Emma
Harrington, Elizabeth A.
Barrett, J. Carl
Pierce, Andrew J. https://orcid.org/0000-0001-9062-0307
Leo, Elisabetta https://orcid.org/0000-0002-9761-8637
Jones, Gemma N. https://orcid.org/0000-0002-7567-681X
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 31 March 2021
Revised: 6 August 2021
Accepted: 17 September 2021
First Online: 18 October 2021
Competing interests
: SEW, CW, MPR, TB, PMC, EVJ, PR, JRC, HKA, FSLN, PMW, DH, ED, EAH, JCB, AJP, EL & GNJ were employees of AstraZeneca during this study. All other authors declare no competing interests.
: All clinical trial human tissues were obtained with fully informed consent and transferred to AstraZeneca. AstraZeneca has a governance framework and processes in place to ensure that commercial sources have appropriate patient consent and ethical approval in place for collection of the samples for research purposes including use by for-profit companies. The AstraZeneca Biobank in the UK is licensed by the Human Tissue Authority (License No. 12109) and has National Research Ethics Service Committee (NREC) approval as a Research Tissue Bank (RTB) (REC No 17/NW/0207) which covers the use of the samples for this project.
: Not applicable.
